What Averitas Pharma does

Averitas Pharma, Inc. is a US-based specialty pharmaceutical company headquartered at 360 Mt. Kemble Avenue, Morristown, NJ, operating as a wholly owned subsidiary of GRT US Holding, Inc. within the Grünenthal group. Founded in 2018, the company was established to commercialize Grünenthal's pain and adjacent portfolios in the United States, leveraging the parent's 75-year heritage in pain management and its TRPV1 receptor agonist platform based on neuronal defunctionalization.

The company markets two FDA-approved prescription products: Qutenza (capsaicin 8% topical system) for neuropathic pain associated with postherpetic neuralgia (PHN) and diabetic peripheral neuropathy (DPN), and Movantik (naloxegol) for opioid-induced constipation in adults with chronic non-cancer pain. Publicly disclosed WAC pricing for Qutenza ranges from $931.15 (single unit) to $3,724.59 (4-unit package), and Movantik is listed at $458.21 (30-count, 12.5mg) and $1,527.40 (100-count, 25mg, HUD only). An additional late-stage pipeline candidate targets chemotherapy-induced peripheral neuropathy (CIPN), addressing an unmet need where no FDA-approved preventive agents currently exist.

Averitas executes a sales-led, enterprise go-to-market motion through regional Key Account Managers (KAMs), Field Access Managers (FAMs), and Medical Science Liaisons deployed across US territories, supplemented by pharmacy/wholesale distribution and a patient support program (My QUTENZA Connect). The company maintains a compliance program aligned with HHS-OIG 2003 pharmaceutical manufacturer guidance and the PhRMA Code, and reports the operations are intended for US residents only. Patient-facing indications target the estimated 2.5 million people living with unresolved diabetic nerve pain and the 12.5% of shingles patients aged ≥50 who develop PHN.

Name

Averitas Pharma

Legal name

Averitas Pharma, Inc.

Website

https://averitaspharma.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

101–250 employees

Short description

Averitas Pharma is a US-based specialty pharmaceutical subsidiary of Grünenthal that commercializes Qutenza (capsaicin 8% topical system) for neuropathic pain and Movantik (naloxegol) for opioid-induced constipation, using an enterprise field sales model targeting US prescribers and healthcare systems.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Neuropathic pain therapeutics
• Prescription pharmaceuticals
• Specialty pain management
• TRPV1 receptor agonists
• Non-opioid analgesics

Headquarters

HQ city

Morristown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Supply Chain, Technology or R&D, Operations, Others

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from commercialized prescription pharmaceutical products Qutenza (capsaicin 8% topical system) for neuropathic pain and Movantik (naloxegol) for opioid-induced constipation. Products are distributed through healthcare providers and pharmacies in the US market.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Averitas Pharma is a U.S.-based specialty pharmaceutical company that develops and commercializes non-opioid prescription medicines for neuropathic pain and related conditions. Its marketed portfolio includes Qutenza (capsaicin 8% topical system) for postherpetic neuralgia and diabetic peripheral neuropathy, and Movantik (naloxegol) for opioid-induced constipation, sold through healthcare providers and pharmacies across the United States.

Product overview

Averitas Pharma is a U.S.-based pharmaceutical company focused on pain management therapeutics. The company operates two marketed products: Qutenza (capsaicin) 8% Topical System for neuropathic pain conditions including postherpetic neuralgia and diabetic peripheral neuropathy, and Movantik (naloxegol) for opioid-induced constipation. The company is a subsidiary of Grünenthal and leverages TRPV1 receptor science for its pipeline development in pain treatment.

Differentiator

Problem solved

Functional benefit

Brands

• Qutenza: Qutenza (capsaicin 8% topical system) is a product marketed by Averitas Pharma for neuropathic pain conditions including postherpetic neuralgia and diabetic peripheral neuropathy.
• Movantik
• My QUTENZA Connect

Products and services

• Qutenza (capsaicin) 8% Topical System A capsaicin 8% topical system applied to the skin to treat neuropathic pain associated with postherpetic neuralgia (PHN) and diabetic peripheral neuropathy (DPN) in adults. Delivered as an in-office procedure by healthcare professionals.
• Movantik (naloxegol) Oral once-daily peripherally acting mu-opioid receptor antagonist tablet indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
• My QUTENZA Connect Patient support program offering SMS-based communications and reimbursement/access assistance services for patients prescribed Qutenza.

Quantifiable outcome

• Qutenza is FDA-approved for neuropathic pain associated with postherpetic neuralgia and diabetic peripheral neuropathy
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered minor and core.

• Mesoblast Ltd.minorStrategic or Co-development PartnerCollaboration with Mesoblast Ltd. noted in pipeline section of the company website. The collaboration involves ongoing studies of investigational products for pain treatment, though specific details of the partnership are not extensively documented on the Averitas website.
• GrünenthalcoreOthersAveritas Pharma is a wholly owned subsidiary of GRT US Holding, Inc. and part of the Grünenthal group of companies. The company is proudly building on the 75-year legacy of Grünenthal, a global privately held healthcare company working toward a world free of pain.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Grünenthal: Parent company and global pain management specialist with 75+ year legacy. Direct peer because it develops, manufactures, and commercializes the same TRPV1-based assets globally that Averitas markets in the US — including Qutenza and the broader pipeline that Averitas eventually commercializes.
• Collegium Pharmaceutical: US specialty pharmaceutical company focused on pain and neurology with branded products like Xtampza ER and Nucynta. Directly comparable as a smaller US-focused commercial-stage pain franchise targeting similar prescriber base.
• Vertex Pharmaceuticals: Recent entrant in non-opioid pain with FDA approval of Journavx (suzetrigine) in January 2025. Competes directly in the broader non-opioid pain category that Averitas addresses and brings substantial R&D and commercial resources to challenge niche pain franchises.

Broad incumbents

• Pfizer (Lyrica): Large pharmaceutical incumbent with Lyrica (pregabalin) historically dominating neuropathic pain including DPN and PHN. Comparable as the established standard-of-care against which Qutenza positions, serving the same patient populations.
• Eli Lilly (Cymbalta): Major pharmaceutical company with duloxetine (Cymbalta), one of the first-line treatments for diabetic peripheral neuropathy. Comparable as established competitor in the same neuropathic pain indications Averitas addresses.
• Daiichi Sankyo: Previously held rights to Movantik (naloxegol) outside the US before divesting to RedHill Biopharma. Comparable as a prior commercializer of one of Averitas's core products and a broader pharmaceutical player with pain portfolio overlap.
• Lundbeck: Global pharmaceutical company with neurology and pain portfolio including treatments for neuropathic pain. Comparable as an established neurology-focused player with overlapping therapeutic areas in central nervous system pain conditions.
• Purdue Pharma: Pain-focused pharmaceutical company with portfolio including legacy opioid and non-opioid products. Comparable for its pain therapeutic focus, though undergoing significant restructuring and operating with different strategic constraints than Averitas.

Emerging players

• Tonix Pharmaceuticals: Emerging specialty pharma with TNX-102 SL in development for pain conditions. Comparable as a smaller company targeting specialty pain indications with innovative mechanisms, though at earlier commercialization stage than Averitas.

Others

• US WorldMeds: Specialty pharmaceutical company that previously held US rights to Qutenza before the asset transferred to Averitas/Grünenthal. Comparable as a specialty pharma commercializer with prior direct involvement in Qutenza commercialization, representing institutional knowledge of the asset.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/averitaspharma

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Averitas Pharma